Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have announced a strategic collaboration to advance the development and manufacturing of antibody-drug conjugates (ADCs), a rapidly growing class of targeted cancer therapies.

The partnership will combine Piramal’s expertise in clinical and commercial-scale ADC manufacturing with Ajinomoto’s proprietary AJICAP™ site-specific conjugation technology, enabling customers to accelerate development timelines and improve production efficiency. 

Under the agreement, both companies will refer clients to each other—Piramal directing customers seeking ADC technology solutions to Ajinomoto, while Ajinomoto will recommend Piramal as a manufacturing partner for AJICAP™-based products. 

As part of the collaboration, the companies also plan to enter into a Material Transfer Agreement (MTA), facilitating technology transfer and equipping Piramal with the capabilities to manufacture AJICAP™-based ADCs with enhanced precision and speed. 

AJICAP™ technology enables the creation of site-specific ADCs with improved efficacy and reduced toxicity, while Piramal brings more than two decades of experience in ADC development and manufacturing, including commercial-scale production and global facility infrastructure. 

The combined offering is expected to provide biopharma companies with an integrated pathway—from early-stage development to commercial manufacturing—helping streamline tech transfer, simplify scale-up, and accelerate the delivery of high-quality ADC therapies to patients worldwide.